Form 8-K BOSTON SCIENTIFIC CORP For: Mar 30
- S&P 500, Nasdaq eye weekly loss as rate-hike worries hit growth stocks
- Foot Locker Erupts 25% After Earnings, Earns Analyst Upgrades as New CEO is a 'Huge Positive'
- Bed Bath & Beyond (BBBY) Crashes 40% on Ryan Cohen Exit, Analyst Warns the Worst is Yet to Come
- Deere (DE) Drops on Big EPS Miss and 'Light' Guidance, Analyst Reactions Mixed
- Market is Betting on Policy Pivot but BofA Warns - Fed is 'Nowhere Near Done'
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 5, 2022 (
March 30, 2022)
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction of incorporation)||(Commission File Number)||(IRS Employer Identification No.)|
(Address of principal executive offices) (Zip Code)
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol||Name of each exchange on which registered|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On March 30, 2022, David A. Pierce, executive vice president and president, MedSurg and president, Endoscopy, informed Boston Scientific Corporation (“Boston Scientific” or the “Company”), that he will retire, effective July 4, 2022. Mr. Pierce joined the Company in 1991 and has served in a number of roles of increasing responsibility. During the next several months, Mr. Pierce intends to lead efforts to transition his responsibilities to his successors.
Arthur C. Butcher, currently executive vice president and president, Asia Pacific, will change roles and serve as executive vice president and group president, MedSurg and Asia Pacific, and will continue to be an executive officer of the Company. Michael Jones, currently senior vice president and general manager, Endoscopy, will change roles and serve as senior vice president and president, Endoscopy. These changes will be effective as of May 2, 2022.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date:||April 5, 2022||BOSTON SCIENTIFIC CORPORATION|
|By:||/s/ Susan J. Thompson|
|Susan J. Thompson|
|Vice President, Chief Corporate Counsel, and Assistant Secretary|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Scientific (BSX) to Acquire Obsidio
- TapeReal Launches a Filter-Free and Algorithm-Free Social Media Platform Aimed at Bolstering Online Authenticity
- Targeted Cancer Vaccines Show Promise in Halting Tumor Progression
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!